Clinical Trials Logo

Substance Withdrawal Syndrome clinical trials

View clinical trials related to Substance Withdrawal Syndrome.

Filter by:

NCT ID: NCT00114439 Completed - Cannabis Dependence Clinical Trials

Lithium Cannabis Withdrawal Study

Start date: September 2005
Phase: Phase 2
Study type: Interventional

This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.

NCT ID: NCT00032968 Completed - Heroin Dependence Clinical Trials

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

Start date: January 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess buprenorphine/naloxone versus clonidine for outpatient opiate detoxification.

NCT ID: NCT00032955 Completed - Heroin Dependence Clinical Trials

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

Start date: February 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess buprenorphine/naloxone versus clonidine for inpatient opiate detoxification.

NCT ID: NCT00000292 Completed - Clinical trials for Substance-Related Disorders

Acute Withdrawal From Smoked Cocaine - 9

Start date: April 1996
Phase: Phase 1
Study type: Interventional

The purpose of this study is to develop an experimental paradigm to examine acute withdrawal symptoms from cocaine.

NCT ID: NCT00000244 Completed - Clinical trials for Opioid-Related Disorders

Effects of Dynorphin 1-13 on Heroin Addiction - 1

Start date: August 1994
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses required to produce the above effects.